These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 32664334)
41. Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Sardo C; Di Domenico EG; Porsio B; De Rocco D; Santucci R; Ascenzioni F; Giammona G; Cavallaro G Int J Pharm; 2019 May; 563():347-357. PubMed ID: 30935918 [TBL] [Abstract][Full Text] [Related]
42. Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas. Sans-Serramitjana E; Jorba M; Fusté E; Pedraz JL; Vinuesa T; Viñas M Microorganisms; 2017 Jun; 5(3):. PubMed ID: 28672861 [TBL] [Abstract][Full Text] [Related]
44. Repurposing the Veterinary Antibiotic Apramycin for Antibacterial and Antibiofilm Activity Against Di Bonaventura G; Lupetti V; Verginelli F; Giancristofaro S; Barbieri R; Gherardi G; Pompilio A Front Microbiol; 2021; 12():801152. PubMed ID: 35185826 [TBL] [Abstract][Full Text] [Related]
45. Gaio V; Lopes N; Cerca N; França A Front Cell Infect Microbiol; 2021; 11():771666. PubMed ID: 34869073 [No Abstract] [Full Text] [Related]
46. Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in Olivares E; Badel-Berchoux S; Provot C; Jaulhac B; Prévost G; Bernardi T; Jehl F Front Microbiol; 2017; 8():1289. PubMed ID: 28744274 [TBL] [Abstract][Full Text] [Related]
47. Tobramycin reduces key virulence determinants in the proteome of Pseudomonas aeruginosa outer membrane vesicles. Koeppen K; Barnaby R; Jackson AA; Gerber SA; Hogan DA; Stanton BA PLoS One; 2019; 14(1):e0211290. PubMed ID: 30682135 [TBL] [Abstract][Full Text] [Related]
48. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967 [TBL] [Abstract][Full Text] [Related]
49. Effect of Shear Stress on Pseudomonas aeruginosa Isolated from the Cystic Fibrosis Lung. Dingemans J; Monsieurs P; Yu SH; Crabbé A; Förstner KU; Malfroot A; Cornelis P; Van Houdt R mBio; 2016 Aug; 7(4):. PubMed ID: 27486191 [TBL] [Abstract][Full Text] [Related]
50. Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Rees VE; Bulitta JB; Oliver A; Nation RL; Landersdorfer CB Pharmaceutics; 2019 Sep; 11(9):. PubMed ID: 31547301 [TBL] [Abstract][Full Text] [Related]
51. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. Riera E; Macià MD; Mena A; Mulet X; Pérez JL; Ge Y; Oliver A J Antimicrob Chemother; 2010 Jul; 65(7):1399-404. PubMed ID: 20435779 [TBL] [Abstract][Full Text] [Related]
53. [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. Liu MT; Sheng MY; Zhang Y; Li Y Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1427-31. PubMed ID: 21756818 [TBL] [Abstract][Full Text] [Related]
54. Postantibiotic effects of subinhibitory concentrations of some antibiotics and their influence on Pseudomonas aeruginosa enzymic activity. Hostacká A Folia Microbiol (Praha); 1996; 41(1):39-42. PubMed ID: 9090822 [TBL] [Abstract][Full Text] [Related]
55. The effect of tobramycin incorporated with bismuth-ethanedithiol loaded on niosomes on the quorum sensing and biofilm formation of Pseudomonas aeruginosa. Mahdiun F; Mansouri S; Khazaeli P; Mirzaei R Microb Pathog; 2017 Jun; 107():129-135. PubMed ID: 28323149 [TBL] [Abstract][Full Text] [Related]
56. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase). Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442 [TBL] [Abstract][Full Text] [Related]
57. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study. Millar BC; Rendall JC; Downey DG; Moore JE J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786 [TBL] [Abstract][Full Text] [Related]
58. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model. Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647 [TBL] [Abstract][Full Text] [Related]
59. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118 [TBL] [Abstract][Full Text] [Related]